

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
29 September 2022 (29.09.2022)



(10) International Publication Number
WO 2022/204299 A1

(51) International Patent Classification:

C07D 239/47 (2006.01) C07D 403/14 (2006.01)
C07D 239/52 (2006.01) C07D 405/14 (2006.01)
C07D 401/12 (2006.01) C07D 413/14 (2006.01)
C07D 401/14 (2006.01) C07D 451/02 (2006.01)
A61P 25/28 (2006.01) A61K 31/506 (2006.01)
C07D 403/12 (2006.01)

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2022/021573

Published:

— with international search report (Art. 21(3))

(22) International Filing Date:

23 March 2022 (23.03.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/164,804 23 March 2021 (23.03.2021) US

(71) Applicant: **HALIA THERAPEUTICS, INC.** [US/US];
1865 W 2100 S, Suite 100, Salt Lake City, Utah 84119 (US).


(72) Inventors: **BEARSS, David J.**; 1865 W 2100 S, Suite 100, Salt Lake City, Utah 84119 (US). **KAUWE, John Sai Keong III**; 1865 W 2100 S, Suite 100, Salt Lake City, Utah 84119 (US). **MOLLARD, Alexis Henri Abel**; 1865 W 2100 S, Suite 100, Salt Lake City, Utah 84119 (US).

(74) Agent: **HARWOOD, Eric, A.** et al.; Seed Intellectual Property Law Group LLP, Suite 5400, 701 Fifth Avenue, Seattle, Washington 98104-7064 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

(54) Title: PYRIMIDINE DERIVATIVES USEFUL AS LRRK2 KINASE INHIBITORS



(57) Abstract: Compounds having activity as inhibitors of LRRK2 kinase are provided. The compounds have Structure (I); or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein A, B, R^{1a}, R^{1b}, R², and L are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of LRRK2 kinase are also provided.

WO 2022/204299 A1